The kinase inhibitors that emerged as potential candidates for PV treatment those targetting p38MAPK, PKC, TK, c‐Src, EGFR, MEK/ERK, mTOR, BTK, and CDK. This evidence concerns the gene EGFR and acquired polycythemia vera.